Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • Andrew Canobi Joshua Rout and Chris Siniakov

  • Dragana Timotijevic

  • Drew Meredith

  • Helen Fisher

  • Ishan Dan

  • Raewyn Williams and Josh McKenzie

Could politicising super depoliticise it?

Coalition Senator Andrew Bragg has been outspoken in his concerns about the growing power of the industry (or union) superannuation sector. Between himself and fellow Coalition member Tim Wilson MP, they are singlehandedly putting the blowtorch on a sector that avoided the worst of the Royal Commission. In a paper this week titled Competition for…

Drew Meredith | 26th Aug 2021 | More
Rethink needed in the pursuit of retirement income

Leading equity manager Martin Currie has suggested the superannuation, advice and wealth management industry may have it all wrong, in its new research piece titled ‘Investing for a sufficient retirement income’. In the paper, chief investment officer Reece Birtles advocates for a “rethink” of the traditional risk-return-dominated approach to portfolio construction, suggesting a “sufficient income…

Drew Meredith | 19th Jul 2021 | More
  • Magellan looks to booming retirement market, launches FuturePay

    Magellan Financial Group (ASX: MFG) last week released its long-awaited new retirement product, called FuturePay. The product launch comes at an important time for the investment and superannuation industry in general, which has seen very little innovation or new product releases focused on delivering more sustainable retirement incomes. So, what is Magellan FuturePay? The product…

    Ishan Dan | 7th Jun 2021 | More
    Pfizer’s Coronavirus vaccine – a closer look

    A major milestone for Pfizer On 9 November 2020, Pfizer announced that its vaccine candidate, developed in collaboration with BioNTech, was more than 90 per cent effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. After discussion with the US Food and Drug Administration (FDA), Pfizer…

    Helen Fisher | 16th Nov 2020 | More
  • Income targeting in a Retirement Portfolio

    Given the Retirement Income Panel’s work over the past year, super funds need no more motivation to answer the critical question: how can funds deliver an adequate pension to retired fund members? The question, however, can’t be answered without determining what an ‘adequate’ pension is. This ResearchBite considers how a hypothetical fund creating an income-targeted…

    Raewyn Williams and Josh McKenzie | 29th Oct 2020 | More
    Finally, a win for retirees

    The ATO delivered some positive news, approving fractional property investment platform Domacom’s’ application to broaden the use of the $300,000 downsizer contribution.

    Drew Meredith | 27th Aug 2020 | More
    Social housing – A potential for good returns while helping those in need

    A nascent asset class is emerging on the back of the roll out of the National Disability Insurance Scheme (NDIS). NDIS is a welfare support scheme of the Australian Government that funds costs associated with disability.

    Dragana Timotijevic | 21st Jul 2020 | More
    There is a problem with retirement incomes but it isn’t the super guarantee

    There is a case for not proceeding with, or at least further deferring, the legislated increase in employers’ compulsory superannuation contributions from 9.5 per cent to 12 per cent.

    Andrew Canobi Joshua Rout and Chris Siniakov | 23rd Jul 2019 | More